


CLINICAL TRIAL

NCT01736592



Low vision

A Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt's Macular Degeneration

Rare Eye Disease concerned by the trial :
Stargardt's disease

Status of the trial : enrolling by invitation
Orphan drug recognition : N/A

Inclusion criteria : Patient must have received a subretinal injection of SAR422459.
Patient must have completed protocol TDU13583 to Week 48 or undergone an early discontinuation visit.

Exclusion criteria : Patient did not receive SAR422459 as part of the TDU13583 protocol



Inclusion opening date : 01/01/2014



Inclusion closing date (previsional) : 01/01/2029

Children



Adults



Within ERN-EYE members



Principal location of the trial :

CHNO des XV XX
28 rue de Charenton
75012 Paris
France

[Contact details](#)



Principal investigator name :


Pr José Alain Sahel



Other investigators :

Dr Saddek Mohand Saïd
Pr Isabelle Audo

CHNO des XV XX



Funder type : Drug company - Industry

[More informations](#)